On the other hand, a high pCR rate up to 71.3% (TCHP) or 85.0% (TCH + Py) was observed in patients with HR-negative breast cancer who were treated with chemotherapy plus dual HER2-blockade. This evidence concerns the gene ERBB2 and breast cancer.